Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK and Safety of DW1809-T2 vs DW1809-1 in Healthy Volunteers
NCT05214690Phase 1Completed
- Sponsor
- Daewon Pharm
- Start
- Aug 2020
- Primary completion
- Sep 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of pelubiprofen in osteoarthritis (OA), rheumatoid arthritis (RA), back pain and 1 more (2 arms), sponsored by Daewon Pharm. Primary endpoints: Peak Plasma Concentration up to 8 hour and Area under the plasma concentration versus time curve up to 8 hour. Started Aug 2020; status: completed.
02
Drugs
pelubiprofen
03
Conditions
osteoarthritis (OA)rheumatoid arthritis (RA)back painacute upper respiratory tract infection (URI)
Beyond the preview
Go deeper on NCT05214690.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05214690.